Metabolism and Pharmacokinetics of Primaquine Enantiomers in Human Volunteers, Study 1
| Status: | Completed |
|---|---|
| Conditions: | Infectious Disease |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - 60 |
| Updated: | 5/17/2018 |
| Start Date: | May 1, 2017 |
| End Date: | March 1, 2018 |
Development of Safer Drugs for Malaria in U.S. Troops, Civilian Personnel, and Travelers: Clinical Evaluation of Primaquine Enantiomer
To investigate the comparative tolerability, metabolism and pharmacokinetics of individual
enantiomers of PQ in healthy human volunteers. The specific aim is the comparative evaluation
of the metabolism, pharmacokinetic behavior, and tolerability of the isomers of PQ (RPQ and
SPQ and the racemic mixture RSPQ) in normal healthy human volunteers.
enantiomers of PQ in healthy human volunteers. The specific aim is the comparative evaluation
of the metabolism, pharmacokinetic behavior, and tolerability of the isomers of PQ (RPQ and
SPQ and the racemic mixture RSPQ) in normal healthy human volunteers.
The primary objective of this project is to investigate the comparative tolerability,
metabolism and pharmacokinetics of individual enantiomers of PQ in healthy human volunteers.
The overall approach is as follows: in 36 healthy volunteers with documented normal G6PD
activity, we will administer a single oral dose of RPQ, SPQ, or RSPQ. At various times after
dosing, we will draw blood samples, in which we will record the plasma levels of the parent
drugs, along with plasma and urinary metabolites. The comparative pharmacokinetics,
tolerability and hematological effects of these two enantiomers and the racemate will be
assessed.
metabolism and pharmacokinetics of individual enantiomers of PQ in healthy human volunteers.
The overall approach is as follows: in 36 healthy volunteers with documented normal G6PD
activity, we will administer a single oral dose of RPQ, SPQ, or RSPQ. At various times after
dosing, we will draw blood samples, in which we will record the plasma levels of the parent
drugs, along with plasma and urinary metabolites. The comparative pharmacokinetics,
tolerability and hematological effects of these two enantiomers and the racemate will be
assessed.
Inclusion Criteria:
- Adults (18-60 years of age)
- Informed consent
- Healthy
Exclusion Criteria:
- Known history of liver, kidney or hematological disease;
- known history of cardiac disease, arrhythmia, QT prolongation;
- Autoimmune disorder;
- Report of an active infection;
- Evidence of G6PD deficiency
We found this trial at
1
site
Click here to add this to my saved trials
